Aberdeen Wealth Management LLC Acquires 375 Shares of Colgate-Palmolive (NYSE:CL)

Aberdeen Wealth Management LLC boosted its holdings in Colgate-Palmolive (NYSE:CLFree Report) by 1.9% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,526 shares of the company’s stock after acquiring an additional 375 shares during the quarter. Colgate-Palmolive accounts for about 1.4% of Aberdeen Wealth Management LLC’s investment portfolio, making the stock its 15th largest position. Aberdeen Wealth Management LLC’s holdings in Colgate-Palmolive were worth $2,131,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its position in Colgate-Palmolive by 27.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 41,067,130 shares of the company’s stock valued at $3,698,096,000 after purchasing an additional 8,933,912 shares during the last quarter. Swedbank AB bought a new stake in shares of Colgate-Palmolive during the 1st quarter worth $286,370,000. Acadian Asset Management LLC grew its position in Colgate-Palmolive by 108.4% in the second quarter. Acadian Asset Management LLC now owns 5,682,280 shares of the company’s stock worth $551,367,000 after acquiring an additional 2,955,442 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Colgate-Palmolive by 40.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 8,969,498 shares of the company’s stock valued at $870,400,000 after acquiring an additional 2,593,313 shares during the last quarter. Finally, Ossiam raised its position in Colgate-Palmolive by 368.4% during the first quarter. Ossiam now owns 1,563,768 shares of the company’s stock valued at $140,817,000 after purchasing an additional 1,229,891 shares in the last quarter. Hedge funds and other institutional investors own 80.41% of the company’s stock.

Insider Activity at Colgate-Palmolive

In related news, Director Martina Hundmejean sold 2,313 shares of Colgate-Palmolive stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $103.86, for a total transaction of $240,228.18. Following the sale, the director now directly owns 11,755 shares in the company, valued at $1,220,874.30. The trade was a 16.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Stanley J. Sutula III sold 45,410 shares of the company’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $94.11, for a total value of $4,273,535.10. Following the completion of the sale, the chief financial officer now directly owns 36,726 shares in the company, valued at approximately $3,456,283.86. The trade was a 55.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.37% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CL shares. Redburn Atlantic upgraded Colgate-Palmolive to a “hold” rating in a research report on Thursday, August 1st. JPMorgan Chase & Co. lifted their price target on shares of Colgate-Palmolive from $113.00 to $114.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Barclays upped their price objective on shares of Colgate-Palmolive from $91.00 to $96.00 and gave the company an “equal weight” rating in a research note on Monday, July 29th. Morgan Stanley lifted their target price on shares of Colgate-Palmolive from $103.00 to $111.00 and gave the stock an “overweight” rating in a research report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Colgate-Palmolive from a “buy” rating to a “hold” rating and upped their price target for the company from $107.00 to $109.00 in a research report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Colgate-Palmolive presently has an average rating of “Moderate Buy” and an average target price of $105.11.

Read Our Latest Analysis on Colgate-Palmolive

Colgate-Palmolive Stock Performance

NYSE:CL opened at $94.65 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 1.04 and a debt-to-equity ratio of 9.46. The firm’s fifty day simple moving average is $99.06 and its 200 day simple moving average is $98.55. The stock has a market cap of $77.33 billion, a P/E ratio of 27.12, a price-to-earnings-growth ratio of 3.34 and a beta of 0.42. Colgate-Palmolive has a twelve month low of $75.17 and a twelve month high of $109.30.

Colgate-Palmolive Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 15th. Stockholders of record on Friday, October 18th were paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.11%. The ex-dividend date of this dividend was Friday, October 18th. Colgate-Palmolive’s payout ratio is 57.31%.

About Colgate-Palmolive

(Free Report)

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.

See Also

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.